{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:49Z","timestamp":1792511929108,"version":"4.5.0"},"reference-count":129,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In the prevention and treatment of infectious diseases, mRNA vaccines hold great promise because of their low risk of insertional mutagenesis, high potency, accelerated development cycles, and potential for low-cost manufacture. In past years, several mRNA vaccines have entered clinical trials and have shown promise for offering solutions to combat emerging and re-emerging infectious diseases such as rabies, Zika, and influenza. Recently, the successful application of mRNA vaccines against COVID-19 has further validated the platform and opened the floodgates to mRNA vaccine\u2019s potential in infectious disease prevention, especially in the veterinary field. In this review, we describe our current understanding of the mRNA vaccines and the technologies used for mRNA vaccine development. We also provide an overview of mRNA vaccines developed for animal infectious diseases and discuss directions and challenges for the future applications of this promising vaccine platform in the veterinary field.<\/jats:p>","DOI":"10.3390\/v14020401","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:44:57Z","timestamp":1644965097000},"page":"401","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases"],"prefix":"10.3390","volume":"14","author":[{"given":"Ting","family":"Le","sequence":"first","affiliation":[{"name":"State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Chang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Departments of Animal Science, School of Agriculture, Ningxia University, Yinchuan 750021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2357-6718","authenticated-orcid":false,"given":"Xin","family":"Yin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, The Chinese Academy of Agricultural Sciences, Harbin 150069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-021-01301-0","article-title":"Vaccine Development for Emerging Infectious Diseases","volume":"27","author":"Excler","year":"2021","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3121\/cmr.1.2.87","article-title":"Smallpox Vaccine: The Good, the Bad, and the Ugly","volume":"1","author":"Belongia","year":"2003","journal-title":"Clin. Med. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1098\/rstb.2012.0139","article-title":"Rinderpest: The Veterinary Perspective on Eradication","volume":"368","author":"Roeder","year":"2013","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18-59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1\/2 Clinical Trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial","volume":"326","author":"Zhang","year":"2021","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, Tolerability, and Immunogenicity of an Aerosolised Adenovirus Type-5 Vector-Based COVID-19 Vaccine (Ad5-NCoV) in Adults: Preliminary Report of an Open-Label and Randomised Phase 1 Clinical Trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 MRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"109493","DOI":"10.1016\/j.celrep.2021.109493","article-title":"Development of Safe and Highly Protective Live-Attenuated SARS-CoV-2 Vaccine Candidates by Genome Recoding","volume":"36","author":"Trimpert","year":"2021","journal-title":"Cell Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2102775118","DOI":"10.1073\/pnas.2102775118","article-title":"Scalable Live-Attenuated SARS-CoV-2 Vaccine Candidate Demonstrates Preclinical Safety and Efficacy","volume":"118","author":"Wang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age","volume":"386","author":"Walter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3389\/fimmu.2021.714170","article-title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis","volume":"12","author":"Sharif","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13037-021-00296-4","article-title":"Correction to: The Safety of Covid-19 MRNA Vaccines: A Review","volume":"15","author":"Anand","year":"2021","journal-title":"Patient Saf. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"MRNA Vaccines\u2014A New Era in Vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"MRNA Vaccines for Infectious Diseases: Principles, Delivery and Clinical Translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 Vaccines: Modes of Immune Activation and Future Challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","article-title":"MRNA Vaccine: A Potential Therapeutic Strategy","volume":"20","author":"Wang","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1098\/rstb.2009.0133","article-title":"Livestock Infectious Diseases and Zoonoses","volume":"364","author":"Tomley","year":"2009","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40249-018-0495-3","article-title":"African Swine Fever: An Unprecedented Disaster and Challenge to China","volume":"7","author":"Wang","year":"2018","journal-title":"Infect. Dis. Poverty"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jmv.25638","article-title":"Prevalence of African Swine Fever in China, 2018\u20132019","volume":"92","author":"Liu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.3201\/eid2411.181274","article-title":"Molecular Characterization of African Swine Fever Virus, China, 2018","volume":"24","author":"Ge","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kumar, N., Chander, Y., Kumar, R., Khandelwal, N., Riyesh, T., Chaudhary, K., Shanmugasundaram, K., Kumar, S., Kumar, A., and Gupta, M.K. (2021). Isolation and Characterization of Lumpy Skin Disease Virus from Cattle in India. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0241022"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"197637","DOI":"10.1016\/j.virusres.2019.05.015","article-title":"Transmission of Lumpy Skin Disease Virus: A Short Review","volume":"269","author":"Sprygin","year":"2019","journal-title":"Virus Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2020.00618","article-title":"Genetic Diversity of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) From 1996 to 2017 in China","volume":"11","author":"Jiang","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fvets.2019.00038","article-title":"Key Gaps in the Knowledge of the Porcine Respiratory Reproductive Syndrome Virus (PRRSV)","volume":"6","author":"Montoya","year":"2019","journal-title":"Front. Vet. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/evj.12600","article-title":"African Horse Sickness: The Potential for an Outbreak in Disease-Free Regions and Current Disease Control and Elimination Techniques","volume":"48","author":"Robin","year":"2016","journal-title":"Equine Vet. J."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rahman, M.T., Sobur, M.A., Islam, M.S., Ievy, S., Hossain, M.J., Zowalaty, M.E.E., Rahman, A.M.M.T., and Ashour, H.M. (2020). Zoonotic Diseases: Etiology, Impact, and Control. Microorganisms, 8.","DOI":"10.3390\/microorganisms8091405"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3389\/fimmu.2020.01181","article-title":"Current Challenges in Vaccinology","volume":"11","author":"Kennedy","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pardi, N. (2021). MRNA Innovates the Vaccine Field. Vaccines, 9.","DOI":"10.3390\/vaccines9050486"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41594-018-0030-z","article-title":"2\u2032-O-Methylation in MRNA Disrupts TRNA Decoding during Translation Elongation","volume":"25","author":"Choi","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1038\/s41467-019-11375-7","article-title":"Modification of Messenger RNA by 2\u2032-O-Methylation Regulates Gene Expression in Vivo","volume":"10","author":"Elliott","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12365","DOI":"10.1093\/nar\/gkaa928","article-title":"2\u2032-O-Methylation Can Increase the Abundance and Lifetime of Alternative RNA Conformational States","volume":"48","author":"Assi","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_34","first-page":"437587","article-title":"Combinatorial Optimization of MRNA Structure, Stability, and Translation for RNA-Based Therapeutics","volume":"29","author":"Leppek","year":"2021","journal-title":"bioRxiv"},{"key":"ref_35","first-page":"2","article-title":"RNA Metabolism: The Short Tail That Wags the MRNA. Nature reviews","volume":"19","author":"Zlotorynski","year":"2018","journal-title":"Mol. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of MRNA Vaccine Structural Elements for Improving MRNA Stability and Translation Efficiency","volume":"18","author":"Kim","year":"2021","journal-title":"Mol. Cell. Toxicol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semcdb.2014.05.018","article-title":"Determinants and Implications of MRNA Poly(A) Tail Size\u2014Does This Protein Make My Tail Look Big?","volume":"34","author":"Jalkanen","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"23068","DOI":"10.1073\/pnas.1821754116","article-title":"Pseudouridinylation of MRNA Coding Sequences Alters Translation","volume":"116","author":"Eyler","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of MRNA Chemistry and Manufacturing Process on Innate Immune Activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biomaterials.2016.09.006","article-title":"Efficacy and Immunogenicity of Unmodified and Pseudouridine-Modified MRNA Delivered Systemically with Lipid Nanoparticles in Vivo","volume":"109","author":"Kauffman","year":"2016","journal-title":"Biomaterials"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1093\/nar\/gkab764","article-title":"Theoretical Basis for Stabilizing Messenger RNA through Secondary Structure Design","volume":"49","author":"Kim","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-Amplifying RNA Vaccines for Infectious Diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1042\/bio_2021_142","article-title":"The next Generation of RNA Vaccines: Self-Amplifying RNA","volume":"43","author":"Blakney","year":"2021","journal-title":"Biochemist"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Blakney, A.K., Ip, S., and Geall, A.J. (2021). An Update on Self-Amplifying MRNA Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9020097"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A Trans-Amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1056\/NEJMcibr2009737","article-title":"Amplifying RNA Vaccine Development","volume":"382","author":"Fuller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"113900","DOI":"10.1016\/j.addr.2021.113900","article-title":"Strategies for Controlling the Innate Immune Activity of Conventional and Self-Amplifying MRNA Therapeutics: Getting the Message Across","volume":"176","author":"Minnaert","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ymthe.2020.11.011","article-title":"Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA","volume":"29","author":"Blakney","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1038\/s41598-019-43422-0","article-title":"In Vitro Evolution of Enhanced RNA Replicons for Immunotherapy","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1089\/hum.2017.121","article-title":"Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins","volume":"28","author":"Beissert","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_51","first-page":"2319","article-title":"Vaccinia Virus Activation and Antagonism of Cytosolic DNA Sensing","volume":"11","author":"Teir","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_52","first-page":"262","article-title":"Gene Gun Delivery of MRNA in Situ Results in Efficient Transgene Expression and Genetic Immunization","volume":"3","author":"Qiu","year":"1996","journal-title":"Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic MRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"MRNA-Lipid Nanoparticle COVID-19 Vaccines: Structure and Stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid Nanoparticles for MRNA Delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"MRNA Vaccine Delivery Using Lipid Nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ejps.2010.05.007","article-title":"Arthemeter-Loaded Lipid Nanoparticles Produced by Modified Thin-Film Hydration: Pharmacokinetics, Toxicological and in Vivo Anti-Malarial Activity","volume":"40","author":"Aditya","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6591-5_2","article-title":"Thin-Film Hydration Followed by Extrusion Method for Liposome Preparation","volume":"1522","author":"Zhang","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1021\/la051654u","article-title":"Preparation of Liposomes Using an Improved Supercritical Reverse Phase Evaporation Method","volume":"22","author":"Otake","year":"2006","journal-title":"Langmuir  ACS J. Surf. Colloids"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"96826","DOI":"10.18632\/oncotarget.18281","article-title":"Microfluidic Hydrodynamic Focusing Synthesis of Polymer-Lipid Nanoparticles for SiRNA Delivery","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.nantod.2016.10.006","article-title":"Microfluidic Hydrodynamic Focusing for Synthesis of Nanomaterials","volume":"11","author":"Lu","year":"2016","journal-title":"Nano Today"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Buschmann, M.D., Carrasco, M.J., Alishetty, S., Paige, M., Alameh, M.G., and Weissman, D. (2021). Nanomaterial Delivery Systems for MRNA Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9010065"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in MRNA Vaccines for Infectious Diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41541-021-00307-6","article-title":"Lipid Nanoparticle Encapsulated Nucleoside-Modified MRNA Vaccines Elicit Polyfunctional HIV-1 Antibodies Comparable to Proteins in Nonhuman Primates","volume":"6","author":"Saunders","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-Modified MRNA Immunization Elicits Influenza Virus Hemagglutinin Stalk-Specific Antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified MRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-Modified MRNA Vaccines Induce Potent T Follicular Helper and Germinal Center B Cell Responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid Nanoparticles Enhance the Efficacy of MRNA and Protein Subunit Vaccines by Inducing Robust T Follicular Helper Cell and Humoral Responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ymthe.2021.03.005","article-title":"RNA-Based Vaccines and Innate Immune Activation: Not Too Hot and Not Too Cold","volume":"29","author":"Frederickson","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring MRNA Vaccine to Balance Innate\/Adaptive Immune Response","volume":"26","author":"Lacroix","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/mt.2016.161","article-title":"Type I Interferons Interfere with the Capacity of MRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses","volume":"24","author":"Pollard","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.molmed.2017.01.006","article-title":"Type I Interferons Modulate CD8 + T Cell Immunity to MRNA Vaccines","volume":"23","author":"Grooten","year":"2017","journal-title":"Trends Mol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of MRNA Vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.2147\/IDR.S341694","article-title":"The Development of MRNA Vaccines for Infectious Diseases: Recent Updates","volume":"14","author":"Nitika","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Oreskovic, Z., Nechvatalova, K., Krejci, J., Kummer, V., and Faldyna, M. (2019). Aspects of Intradermal Immunization with Different Adjuvants: The Role of Dendritic Cells and Th1\/Th2 Response. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211896"},{"key":"ref_76","first-page":"1","article-title":"Formulation and Delivery Technologies for MRNA Vaccines","volume":"6","author":"Zeng","year":"2020","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1297-9716-44-116","article-title":"Foot-and-Mouth Disease: Past, Present and Future","volume":"44","author":"Jamal","year":"2013","journal-title":"Vet. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13028-020-00519-1","article-title":"Towards Improvements in Foot-and-Mouth Disease Vaccine Performance","volume":"62","author":"Belsham","year":"2020","journal-title":"Acta Vet. Scand."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.antiviral.2009.12.005","article-title":"RNA Immunization Can Protect Mice against Foot-and-Mouth Disease Virus","volume":"85","author":"Pulido","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.antiviral.2011.10.005","article-title":"Inoculation of Newborn Mice with Non-Coding Regions of Foot-and-Mouth Disease Virus RNA Can Induce a Rapid, Solid and Wide-Range Protection against Viral Infection","volume":"92","author":"Sobrino","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1016\/j.vaccine.2013.07.008","article-title":"Delivery of Synthetic RNA Can Enhance the Immunogenicity of Vaccines against Foot-and-Mouth Disease Virus (FMDV) in Mice","volume":"31","author":"Borrego","year":"2013","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Newman, J., Rowlands, D.J., and Tuthill, T.J. (2021). An Engineered Maturation Cleavage Provides a Recombinant Mimic of Foot-and-Mouth Disease Virus Capsid Assembly-Disassembly. Life, 11.","DOI":"10.3390\/life11060500"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fvets.2021.633706","article-title":"The High Immunity Induced by the Virus-Like Particles of Foot-and-Mouth Disease Virus Serotype O","volume":"8","author":"Xiao","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1586\/14760584.2015.973403","article-title":"Rabies Vaccines: Where Do We Stand, Where Are We Heading?","volume":"14","author":"Kaur","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Armbruster, N., Jasny, E., and Petsch, B. (2019). Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies. Vaccines, 7.","DOI":"10.3390\/vaccines7040132"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and Immunogenicity of a MRNA Rabies Vaccine in Healthy Adults: An Open-Label, Non-Randomised, Prospective, First-in-Human Phase 1 Clinical Trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Stitz, L., Vogel, A., Schnee, M., Voss, D., Rauch, S., Mutzke, T., Ketterer, T., Kramps, T., and Petsch, B. (2017). A Thermostable Messenger RNA Based Vaccine against Rabies. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0006108"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Schnee, M., Vogel, A.B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., and Stitz, L. (2016). An MRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004746"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-Concept of a Low-Dose Unmodified MRNA-Based Rabies Vaccine Formulated with Lipid Nanoparticles in Human Volunteers: A Phase 1 Trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"104648","DOI":"10.1016\/j.yrtph.2020.104648","article-title":"Nonclinical Safety Assessment of Repeated Administration and Biodistribution of a Novel Rabies Self-Amplifying MRNA Vaccine in Rats","volume":"113","author":"Stokes","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/cid\/ciq012","article-title":"Estimating the Burden of 2009 Pandemic Influenza A (H1N1) in the United States (April 2009\u2013April 2010)","volume":"52","author":"Shrestha","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2105\/AJPH.2019.305557","article-title":"Fifty Years of Influenza A(H3N2) Following the Pandemic of 1968","volume":"110","author":"Jester","year":"2020","journal-title":"Am. J. Public Health"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to MRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Magini, D., Giovani, C., Mangiavacchi, S., MacCari, S., Cecchi, R., Ulmer, J.B., de Gregorio, E., Geall, A.J., Brazzoli, M., and Bertholet, S. (2016). Self-Amplifying MRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161193"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1038\/mtna.2014.24","article-title":"Self-Replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-Nanoparticles for Translation In Vitro and In Vivo. Molecular therapy","volume":"3","author":"McCullough","year":"2014","journal-title":"Nucleic Acids"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A Multi-Targeting, Nucleoside-Modified MRNA Influenza Virus Vaccine Provides Broad Protection in Mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_97","first-page":"1365","article-title":"Moderna\u2019s MRNA Vaccine for Seasonal Flu Enters Clinical Trials","volume":"326","author":"Abbasi","year":"2021","journal-title":"JAMA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/4031","article-title":"In Vitro-Synthesized Infectious RNA as an Attenuated Live Vaccine in a Flavivirus Model","volume":"4","author":"Mandl","year":"1998","journal-title":"Nat. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"15107","DOI":"10.1128\/JVI.79.24.15107-15113.2005","article-title":"Humoral and Cellular Immune Response to RNA Immunization with Flavivirus Replicons Derived from Tick-Borne Encephalitis Virus","volume":"79","author":"Aberle","year":"2005","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1073\/pnas.0307145101","article-title":"Mimicking Live Flavivirus Immunization with a Noninfectious RNA Vaccine","volume":"101","author":"Kofler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/319857","article-title":"Self-Replicative RNA Vaccines Elicit Protection against Influenza A Virus, Respiratory Syncytial Virus, and a Tickborne Encephalitis Virus","volume":"183","author":"Fleeton","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","article-title":"Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease","volume":"170","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Pattnaik, A., Sahoo, B.R., and Pattnaik, A.K. (2020). Current Status of Zika Virus Vaccines: Successes and Challenges. Vaccines, 8.","DOI":"10.3390\/vaccines8020266"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3389\/fimmu.2019.01424","article-title":"A Modified MRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice","volume":"10","author":"Roth","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified MRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice. Molecular therapy","volume":"18","author":"Zhang","year":"2020","journal-title":"Methods Clin. Dev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.celrep.2018.11.082","article-title":"An MRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections","volume":"25","author":"VanBlargan","year":"2018","journal-title":"Cell Rep."},{"key":"ref_108","first-page":"171","article-title":"T Cell Responses to Viral Infections\u2014Opportunities for Peptide Vaccination","volume":"5","author":"Huber","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/22221751.2019.1590128","article-title":"Replication and Virulence in Pigs of the First African Swine Fever Virus Isolated in China","volume":"8","author":"Zhao","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11427-020-1657-9","article-title":"A Seven-Gene-Deleted African Swine Fever Virus Is Safe and Effective as a Live Attenuated Vaccine in Pigs. Science China","volume":"63","author":"Chen","year":"2020","journal-title":"Life Sci."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Borca, M.V., Ramirez-Medina, E., Silva, E., Vuono, E., Rai, A., Pruitt, S., Espinoza, N., Velazquez-Salinas, L., Gay, C.G., and Gladue, D.P. (2021). ASFV-G-\u2206I177L as an Effective Oral Nasal Vaccine against the Eurasia Strain of Africa Swine Fever. Viruses, 13.","DOI":"10.3390\/v13050765"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e02017-19","DOI":"10.1128\/JVI.02017-19","article-title":"Development of a Highly Effective African Swine Fever Virus Vaccine by Deletion of the I177L Gene Results in Sterile Immunity against the Current Epidemic Eurasia Strain","volume":"94","author":"Borca","year":"2020","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Ros-Lucas, A., Correa-Fiz, F., Bosch-Cam\u00f3s, L., Rodriguez, F., and Alonso-Padilla, J. (2020). Computational Analysis of African Swine Fever Virus Protein Space for the Design of an Epitope-Based Vaccine Ensemble. Pathogens, 9.","DOI":"10.3390\/pathogens9121078"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Bosch-Cam\u00f3s, L., L\u00f3pez, E., Navas, M.J., Pina-Pedrero, S., Accensi, F., Correa-Fiz, F., Park, C., Carrascal, M., Dom\u00ednguez, J., and Salas, M.L. (2021). Identification of Promiscuous African Swine Fever Virus T-Cell Determinants Using a Multiple Technical Approach. Vaccines, 9.","DOI":"10.3390\/vaccines9010029"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1099\/jgv.0.001195","article-title":"Identification of T-Cell Epitopes in African Swine Fever Virus CD2v and C-Type Lectin Proteins","volume":"100","author":"Burmakina","year":"2019","journal-title":"J. Gen. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3389\/fimmu.2020.563362","article-title":"New Immunoinformatics Tools for Swine: Designing Epitope-Driven Vaccines, Predicting Vaccine Efficacy, and Making Vaccines on Demand","volume":"11","author":"Moise","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.vetimm.2018.11.018","article-title":"Evaluation of a Viral DNA-Protein Immunization Strategy against African Swine Fever in Domestic Pigs","volume":"208","author":"Sunwoo","year":"2019","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"10781","DOI":"10.1038\/s41598-019-47239-9","article-title":"Efficacy of Type 2 PRRSV Vaccine against Challenge with the Chinese Lineage 1 (NADC30-like) PRRSVs in Pigs","volume":"9","author":"Wei","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12985-017-0735-3","article-title":"Emergence of Mosaic Recombinant Strains Potentially Associated with Vaccine JXA1-R and Predominant Circulating Strains of Porcine Reproductive and Respiratory Syndrome Virus in Different Provinces of China","volume":"14","author":"Zhao","year":"2017","journal-title":"Virol. J."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Eclercy, J., Renson, P., Lebret, A., Hirchaud, E., Normand, V., Andraud, M., Paboeuf, F., Blanchard, Y., Rose, N., and Bourry, O. (2019). A Field Recombinant Strain Derived from Two Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV-1) Modified Live Vaccines Shows Increased Viremia and Transmission in SPF Pigs. Viruses, 11.","DOI":"10.3390\/v11030296"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Cui, J., O\u2019connell, C.M., Hagen, C., Sawicki, K., Smyth, J.A., Verardi, P.H., van Kruiningen, H.J., and Garmendia, A.E. (2020). Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime\/GP5-Mosaic RVaccinia (VACV) Vaccine Boost. Vaccines, 8.","DOI":"10.3390\/vaccines8010106"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Cui, J., O\u2019Connell, C.M., Costa, A., Pan, Y., Smyth, J.A., Verardi, P.H., Burgess, D.J., van Kruiningen, H.J., and Garmendia, A.E. (2019). A PRRSV GP5-Mosaic Vaccine: Protection of Pigs from Challenge and Ex Vivo Detection of IFN\u03b3 Responses against Several Genotype 2 Strains. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0208801"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.virusres.2007.03.012","article-title":"A Review of Studies on Animal Reservoirs of the SARS Coronavirus","volume":"133","author":"Shi","year":"2008","journal-title":"Virus Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 Vaccine BNT162b1 Elicits Human Antibody and T H 1 T Cell Responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II Study of COVID-19 RNA Vaccine BNT162b1 in Adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"eabi9915","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies Elicited by MRNA-1273 Vaccination Bind More Broadly to the Receptor Binding Domain than Do Those from SARS-CoV-2 Infection","volume":"13","author":"Greaney","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/088282404322875421","article-title":"Induction of T Lymphocytes Specific for Bovine Viral Diarrhea Virus in Calves with Maternal Antibody","volume":"17","author":"Endsley","year":"2004","journal-title":"Viral Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1128\/CVI.00415-13","article-title":"Assessment of the Phenotype and Functionality of Porcine CD8 T Cell Responses Following Vaccination with Live Attenuated Classical Swine Fever Virus (CSFV) and Virulent CSFV Challenge","volume":"20","author":"Franzoni","year":"2013","journal-title":"Clin. Vaccine Immunol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/2\/401\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:20:10Z","timestamp":1760134810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/2\/401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":129,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["v14020401"],"URL":"https:\/\/doi.org\/10.3390\/v14020401","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}